JMJiaqi Meng

Jiaqi Meng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiaqi Meng has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Bolun Zhu

    Department of General Surgery, Hepatobiliary Surgery Center, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China

    1 shared publication
  • Hao Wang

    Hepatobiliary Surgery Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China; Cancer Metastasis Institute, Fudan University, Shanghai, China

    1 shared publication
  • Jixuan Chen

    Hepatobiliary Surgery, Department of General Surgery, Cancer Metastasis Institute, Huashan Hospital, Fudan University, Shanghai 200437, China

    1 shared publication
  • Junjie Pan

    Department of General Surgery, Hepatobiliary Surgery Center, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China

    1 shared publication
  • Lu Lu

    Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China

    1 shared publication
  • Lu-Yu Yang

    Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma

    by Xin Zheng, Luyu Yang, Xiaotian Shen, Junjie Pan, Yiran Chen, Jixuan Chen, Hao Wang, Jiaqi Meng, Zhenchao Chen, Sunzhe Xie, et al.

    Background: Immune escape is an important feature of hepatocellular carcinoma (HCC). The overall response rate of immune checkpoint inhibitors (ICIs) in HCC is still limited. Revealing the immune regulation mechanisms and finding new immune targets are expected to further improve the efficacy of immunotherapy. Our study aims to use CRISPR screening mice models to identify potential targets that play a critical role in HCC immune evasion and further explore their value in improving immunotherapy. Methods: We performed CRISPR screening in two mice models with different immune backgrounds (C57BL/6 and NPG mice) and identified the immunosuppressive gene Gsk3a as a candidate for further investigation. Flow cytometry was used to analyze the impact of Gsk3a on immune cell infiltration and T-cell function. RNA sequencing was used to identify the changes in neutrophil gene expression induced by Gsk3a and alterations in downstream molecules. The therapeutic value of the combination of Gsk3a inhibitors and anti-programmed cell death protein-1 (PD-1) antibody was also explored. Results: Gsk3a, as an immune inhibitory target, significantly promoted tumor growth in immunocompetent mice rather than immune-deficient mice. Gsk3a inhibited cytotoxic T lymphocytes (CTLs) function by inducing neutrophil chemotaxis. Gsk3a promoted self-chemotaxis of neutrophil expression profiles and neutrophil extracellular traps (NETs) formation to block T-cell activity through leucine-rich α-2-glycoprotein 1 (LRG1). A significant synergistic effect was observed when Gsk3a inhibitor was in combination with anti-PD-1 antibody. Conclusions: We identified a potential HCC immune evasion target, Gsk3a, through CRISPR screening. Gsk3a induces neutrophil recruitment and NETs formation through the intermediate molecule LRG1, leading to the inhibition of CTLs function. Targeting Gsk3a can enhance CTLs function and improve the efficacy of ICIs.